Multicenter validation of the value of BASFI and BASDAI in Chinese ankylosing spondylitis and undifferentiated spondyloarthropathy patients

Rheumatology International

Volumn 31, Issue 2, 2011, Pages 233-238

  Lin, Zhiming ^a   Gu, Jieruo ^a   He, Peigen ^b   Gao, Jiesheng ^c   Zuo, Xiaoxia ^d   Ye, Zhizhong ^e   Shao, Fengmin ^f   Zhan, Feng ^g   Lin, Jinying ^h   Li, Li ^a   Wei, Yanlin ^a   Xu, Manlong ^a   Liao, Zetao ^a   Lin, Qu ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d CENTRAL SOUTH UNIVERSITY   (China)

^e GUANGDONG MEDICAL UNIVERSITY   (China)

^f HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^g HAINAN PROVINCIAL PEOPLE S HOSPITAL   (China)

^h Department of Rheumatology   (China)

Author keywords

Ankylosing spondylitis; BASDAI; BASFI; Reliability

Indexed keywords

C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; CHINESE; CORRELATION ANALYSIS; DISEASE ACTIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ONSET AGE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUESTIONNAIRE; REFERENCE VALUE; RELIABILITY; SCORING SYSTEM; SPINE RADIOGRAPHY; SPONDYLOARTHROPATHY; TEST RETEST RELIABILITY; TREATMENT RESPONSE; VALIDATION STUDY; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DISABILITY EVALUATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; QUESTIONNAIRES; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; SPONDYLARTHROPATHIES; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 79954443245     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-009-1313-9     Document Type: Article

References (20)

1. Boonen A, Chorus A, Midema H, van der Heijde D, van der Tempel H, van der Linden S (2001) Employment, work disability and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 60:353-358 (Pubitemid 32242748)
2. Calin A, Garrel S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P et al (1994) A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath ankylosing spondylitis functional index. J Rheumatol 21:2281-2285
3. Garret S, Ienkinson T, Kennedy G, Whitelock H, Gaisford P, Calin A (1994) A new approach to defining disease status in ankylosing spondylitis: the Bath ankylosing spondylitis disease activity index. J Rheumatol 21:2286-2291
4. Van der Heijde D, Dougados M, Davis J, Weisman M, Maksymowych W, Braun J et al (2005) Assessment in Ankylosing Spondylitis International Working Group/Spondylitis Association of America recommendation for conducting clinical trials in ankylosing spondylitis. Arthritis Rheum 52:386-394 (Pubitemid 40216302)
5. Van der Heijde D, Calin A, Dougados M, Khan MA, van der Linden S et al (1999) Selection of instruments in the core set for DC-ART, SMARD, physical therapy and clinical record keeping in ankylosing spondylitis: progress report of the ASAS Working Group. J Rheumatol 26:951-954 (Pubitemid 29195692)
6. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A et al (1991) The European Spondyloarthropathy Study Group preliminary criteria for the classification spondyloarthropathy. Arthritis Rheum 34:1218-1227
7. Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, de Vlam K, Mielants H et al (1999) A comparative study of the usefulness of the Bath ankylosing spondylitis functional index and the Dougados functional index in the assessment of ankylosing spondylitis. J Rheumatol 26:961-965 (Pubitemid 29195694)
8. Heikkilä S, Viitanen JV, Kautianen H, Kauppi M (2000) Evaluation of the Finnish versions of the functional indices BASFI and DFI in spondylarthropathy. Clin Rheumatol 19:464-469 (Pubitemid 32039667)
9. Cardiel MH, Londoño JD, Gutiérrez E, Pacheco-Tena C, Vázquez-Mellado J, Burgos-Vargas R (2003) Translation, crosscultural adaptation, and validation of the Bath ankylosing spondylitis functional index (BASFI), the Bath ankylosing spondylitis disease activity index (BASDAI) and the Dougados functional index (DFI) in a Spanish speaking population with spondyloarthropathies. Clin Exp Rheumatol 21:451-458 (Pubitemid 36950313)
10. Salaffi F, Stancati A, Silvestri A, Carotti M, Grassi W (2005) Validation of the Italian versions of the Bath ankylosing spondylitis functional index (BASFI) and the Dougados functional index (DFI) in patients with ankylosing spondylitis. Reumatismo 57:161-173 (Pubitemid 41441652)
11. El Miedany Y, Youssef S, Mehanna A, Shebrya N, Abu Gamra S, El Gaafary M (2008) Defining disease status in ankylosing spondylitis: validation and cross-cultural adaptation of the Arabic Bath ankylosing spondylitis functional index (BASFI), the Bath ankylosing spondylitis disease activity index (BASDAI) and the Bath ankylosing spondylitis global score (BASG). Clin Rheumatol 27:605-612
12. Claudepierre P, Sibila J, Goupille P, Flipo RM, Wendling D, Eulry F et al (1997) Evaluation of a French version of the Bath ankylosing spondylitis disease activity index in patients with spondylarthropathy. J Rheumatol 24:1954-1958 (Pubitemid 27431928)
13. Keikkila S, Vitanen JV, Kautiainen H, Kauppi M (2002) Functional long term changes in patients with spondyloarthropathy. Clin Rheumatol 21:119-122 (Pubitemid 34649592)
14. Brandt J, Khariouzov A, Listing J, Haibel H, Sörensen H, Grassnickel L et al (2003) Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48:1667-1675 (Pubitemid 36682375)
15. Brandt J, Listing J, Haibel H, Sörensen H, Schwebig A, Rudwaleit M et al (2005) Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology 44:342-348 (Pubitemid 40361291)
16. Davis JC, Van der Heijde D, Braun J, Dougados M, Cush J, Clegg DO et al (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48:3230-3236 (Pubitemid 37409337)
17. Calin A, Dijkmans BA, Emery P, Hakala M, Kalden J, Leirisalo-Repo M et al (2004) Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63:1594-1600 (Pubitemid 39573687)
18. Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R et al (2005) Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology 44:670-676 (Pubitemid 41487242)
19. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P et al (2005) Ankylosing spondylitis study for the evaluation of Recombinant Infliximab Therapy Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52:582-591 (Pubitemid 40216323)
20. Gossec L, Le Henanff A, Breban M, Vignon E, Claudepierre P, Devauchelle V et al (2006) Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up. Rheumatology 45:859-862 (Pubitemid 43985376)